Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02482454

Enrollment

Registered

2015-06-26

Start date

2012-07-31

Completion date

2033-07-31

Last updated

2017-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma

Keywords

radiofrequency ablation, cytokine-induced killer cells, cholangiocarcinoma

Brief summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.

Detailed description

The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cholangiocarcinoma.

Interventions

PROCEDURERadiofrequency ablation

Radiofrequency ablation is performed percutaneously under CT/US guidance

BIOLOGICALCytokine-induced killer cells

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with histologically confirmed cholangiocarcinoma * Primary lesions (cholangiocarcinoma) are not resected * Serum bilirubin level of 2.0 mg/dl or less. * Performance status of 0 or 1. * Expected survival of 1 year or more. * Informed consent from the patient.

Exclusion criteria

* With extrahepatic metastases * With other neoplastic disease that is measurable or being treated other than cholangiocarcinoma.

Design outcomes

Primary

Measure	Time frame	Description
Recurrence-free survival	1 year	Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.

Secondary

Measure	Time frame	Description
Adverse events	4 weeks	Adverse events related to RFA and CIK treatments.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026